The current state of the art and future trends in RAS-targeted cancer therapies
Punekar S, Velcheti V, Neel B, Wong K. The current state of the art and future trends in RAS-targeted cancer therapies. Nature Reviews Clinical Oncology 2022, 19: 637-655. PMID: 36028717, PMCID: PMC9412785, DOI: 10.1038/s41571-022-00671-9.Peer-Reviewed Original ResearchConceptsDuration of responseNovel combination therapiesCombination therapyClinical trialsTherapeutic strategiesSolid tumorsMutant KRASTumor microenvironmentDrug resistanceRAS pathwayCancer cellsDevelopment of inhibitorsCancer therapyOncogenic RASPatientsOncogenic proteinsTherapyKRASResistance mechanismsMutant isoformsInhibitorsRASMalignancyTumorsCancerImmunotherapy in non-small cell lung cancer: Past, present, and future directions
Punekar S, Shum E, Grello C, Lau S, Velcheti V. Immunotherapy in non-small cell lung cancer: Past, present, and future directions. Frontiers In Oncology 2022, 12: 877594. PMID: 35992832, PMCID: PMC9382405, DOI: 10.3389/fonc.2022.877594.Peer-Reviewed Original ResearchNon-small cell lung cancerImmune checkpoint blockadeProgression-free survivalCell lung cancerLung cancerAnti-cytotoxic T-lymphocyte-associated protein 4 antibodyAnti-programmed death-1 antibodyDeath-1 antibodyFuture of immunotherapyOverall survival benefitProtein 4 antibodyViable therapeutic approachIdentification of biomarkersFree survivalCheckpoint blockadeDurable responsesSurvival benefitModulating therapiesCombination therapyClinical trialsTherapeutic approachesImmunotherapyFuture careLigand antibodyCellular therapyPneumonitis in immunotherapy alone vs. chemoimmunotherapy: A systematic review and meta-analysis.
Barbaro A, Siskin M, Grello C, Hernandez A, Dublin J, Breslin S, Punekar S, Velcheti V. Pneumonitis in immunotherapy alone vs. chemoimmunotherapy: A systematic review and meta-analysis. Journal Of Clinical Oncology 2022, 40: e21120-e21120. DOI: 10.1200/jco.2022.40.16_suppl.e21120.Peer-Reviewed Original ResearchNon-small cell lung cancerImmune related adverse eventsImmune checkpoint inhibitorsAdvanced non-small cell lung cancerSevere pneumonitisPD-L1Combination therapyCTLA-4Use of ICIsCombination immune checkpoint inhibitorsLife-threatening complicationsRelated adverse eventsCell lung cancerLung cancer patientsT cell populationsInverse variance weightingGrade pneumonitisCheckpoint inhibitorsInterventional armAdverse eventsCytotoxic chemotherapyImmune suppressionCancer patientsLung cancerClinical trials